Dual GIP/GLP-1 receptor agonist researched for glycemic control and weight management.
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, representing a novel class of peptides for metabolic research. It has shown remarkable efficacy in clinical studies for glycemic control and weight reduction, surpassing single-agonist approaches.
| Purity | ≥99% |
| Grade | Pharma |
| Form | Lyophilized powder |
| Volume | 3ml vial |
For laboratory research purposes only. Not for human consumption.